Trends in Glucagon-Like Peptide 1 Receptor Agonist Prescribing Patterns
From 2018 to 2023, GLP-1 RA prescribing increased significantly, with semaglutide approved for weight loss rising to 60% share in the nondiabetic obese/overweight group. Trends showed a notable rise in prescriptions for nondiabetic and obese/overweight patients.
Authors
- Maria Ukhanova (ORCID: https://orcid.org/0000-0003-1143-3461)
Institutions
- The University of Texas Health Science Center at Houston (US)
Publication Details
- Journal
- The American Journal of Managed Care
- Published
- 2025-08-15
- DOI
- https://doi.org/10.37765/ajmc.2025.89778
- Citations
- 19
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 24.60
Funders
- CSL Behring